DSP107 + Atezolizumab for Solid Tumors
Trial Summary
The trial protocol does not specify if you must stop taking your current medications. However, you cannot take systemic immunosuppressive medication within 2 weeks before the first dose, or systemic immunostimulatory agents within 4 weeks before the first dose. Also, you cannot have received a live, attenuated vaccine within 4 weeks before the first dose.
The available research shows that Atezolizumab, when used in combination with other treatments, has been effective for various types of cancer, such as lung cancer and breast cancer. For example, in studies like IMpower150 and IMpower130, Atezolizumab combined with other drugs improved survival rates for patients with lung cancer. However, there is no specific data provided here about DSP107 combined with Atezolizumab for solid tumors, so we can't directly compare its effectiveness to other treatments based on this information.
12345The safety data for Atezolizumab (Tecentriq) is well-documented across various studies and trials. It has been evaluated for safety in multiple cancer types, including urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, alveolar soft part sarcoma, and melanoma. Atezolizumab has shown a consistent safety profile as a single agent and in combination with chemotherapy. However, specific safety data for the combination of DSP107 and Atezolizumab is not detailed in the provided research.
12346Yes, Atezolizumab is a promising drug. It has been approved for treating several types of cancer, including bladder cancer, lung cancer, and a rare type of soft tissue cancer. It works by helping the immune system fight cancer cells more effectively. This drug has shown positive results in clinical trials, making it a hopeful option for treating solid tumors.
12347Eligibility Criteria
This trial is for adults with advanced solid tumors, including non-small cell lung cancer and colorectal cancer. Participants must have measurable disease, an ECOG status of 0 or 1, no more than two prior treatments (excluding certain targeted therapies), and cannot have a history of severe autoimmune diseases, CNS metastases, organ transplants, significant liver disease or recent immunosuppressive treatment.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma